• Earlier this week, Morningstar launched the Morningstar PitchBook GenAI 20 Index, a perpetual benchmark designed to track pure-play generative AI companies from late-stage private funding through their public listings.
• By continuously following GenAI innovators across private and public markets, the index offers a rare, unified lens on companies whose core businesses center on machine learning, natural language processing, computer vision, and agentic AI.
• Next, we will examine how this new GenAI 20 benchmark, spanning private-to-public AI leaders, could shape Morningstar’s broader investment narrative.

The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

What Is Morningstar's Investment Narrative?

For shareholders in Morningstar, the core belief is that its data, ratings, and index franchises remain essential infrastructure for investors, and that disciplined capital allocation can justify a premium multiple despite modest forecast growth. The launch of the Morningstar PitchBook GenAI 20 Index fits neatly into that story as a brand and relevance catalyst, reinforcing Morningstar’s role in indexing and private-market data rather than transforming the near term earnings outlook. Given the share price’s sharp 1‑year decline and a still‑full valuation versus some intrinsic estimates, this new GenAI benchmark, along with the PIMFA index win and fresh retirement research, looks more like incremental support for the existing thesis than a step change in fundamentals. The bigger swing factors remain execution on new products, management depth, and how investors reassess what they are willing to pay for the franchise.

However, investors should be aware that Morningstar’s valuation still embeds meaningful execution risk. Morningstar's share price has been on the slide but might be dropping deeper into value territory. Find out whether it's a bargain at this price.

Exploring Other Perspectives

Eight fair value estimates from the Simply Wall St Community range widely from about US$99,900 to a very large US$595,650, reflecting very different views on Morningstar’s long term potential. Against that backdrop, the GenAI 20 Index launch and expanding index footprint may appeal to some as reinforcing the business story, while others could focus more on concentration and execution risks. You can weigh these contrasting perspectives to decide which narrative you find more convincing.

Explore 8 other fair value estimates on Morningstar - why the stock might be worth less than half the current price!

Build Your Own Morningstar Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Morningstar research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Morningstar research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Morningstar's overall financial health at a glance.

Interested In Other Possibilities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Find companies with promising cash flow potential yet trading below their fair value.
• We've found 12 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• AI is about to change healthcare. These 109 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.